市場調査レポート

商品コード

1193092

認知症治療薬市場：適応症別、薬物クラス別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Dementia Drugs Market By Indication, By Drug Class, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: 2022年10月01日 | 発行: Allied Market Research

| ページ情報: 英文 265 Pages | 納期: 2～3営業日

価格

PDF (Single User License)

USD 5,730 898,234円

レポートPDFを1つのPCでご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回だけ可能です。印刷したレポートの利用もPDFのライセンス保持者になります。回覧のための複製も原則NGです。

PDF (5-user License)

USD 6,450 1,011,102円

レポートPDFを5名でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回可能です。印刷したレポートの利用もPDFのライセンス保持者5名となります。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,504,896円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

認知症治療薬の世界市場は、2021年に86億6,217万米ドルを記録し、2022年から2031年にかけてCAGR8.5%を記録し、2031年には197億427万米ドルに達すると予測されます。

認知症は、思考、行動、記憶、日常生活動作の能力に劣化が見られる症候群です。最も一般的な認知症の形態はアルツハイマー病です。認知症は、主に、または二次的に脳に影響を与える多くの傷害や疾患によって引き起こされます。認知症に対する認識が低く、その結果、検査や介護に支障をきたしている場合が多くあります。コリンエステラーゼ阻害剤は、最も一般的に処方される薬剤で、学習や記憶、気分転換に不可欠なアセチルコリンの脳内分解を抑制する働きがあります。

認知症治療薬市場は、アルツハイマー病の有病率の増加、医薬品開発のための研究開発活動の進展、早期診断の普及などにより、予測期間中に大きく成長するものと思われます。また、高齢者人口の増加、研究開発への投資の増加、強力なパイプライン候補の存在、ヘルスケアインフラの整備に向けた支出の増加、発展途上地域における疾病予防に関する国民の意識の高まり、個別化医療に対する需要の高まりなどが、市場の成長をさらに促進しています。しかし、製品承認に関連する政府の厳しい規制や研究開発活動に関連する高コストが市場成長の妨げになると予想されます。一方、創薬技術における技術進歩の加速や、政府による医薬品開発への高投資は、業界に新たな道を開く要因であり、認知症治療薬市場に大きな成長機会をもたらすと予想されます。

認知症治療薬市場は、適応症、薬物クラス、流通チャネル、地域に基づいて区分されています。適応症別では、レビー小体型認知症、パーキンソン病型認知症、アルツハイマー病、血管性認知症、その他の適応症に二分され、薬物クラス別では、レビー小体型認知症、パーキンソン病型認知症、アルツハイマー病型認知症、血管性認知症、その他の適応症に二分されます。薬物クラスにより、市場はコリンエステラーゼ阻害剤とNMDA拮抗剤およびその併用薬に分類されます。流通経路別では、病院薬局、小売薬局、オンライン薬局に分類されます。

概要
- 市場規模および予測
レビー小体型認知症
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
パーキンソンズ病型認知症
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
アルツハイマー型認知症
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
血管性認知症
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
その他の適応症
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別

第5章認知症治療薬市場：薬効分類別

概要
- 市場規模および予測
コリンエステラーゼ阻害剤
- 主な市場動向、成長要因、機会
- 市場規模および予測：地域別
- 市場シェア分析：国別
NMDA拮抗薬とその併用薬
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別

第6章認知症治療薬市場：流通チャネル別

概要
- 市場規模・予測
小売薬局
- 主な市場動向、成長要因と機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
病院薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別
オンライン薬局
- 主な市場動向、成長要因、機会
- 市場規模・予測：地域別
- 市場シェア分析：国別

第7章認知症治療薬市場：地域別

概要
- 市場規模・予測
北米
- 主要動向と機会
- 北米市場規模・予測：適応症別
- 北米市場規模・予測：薬物クラス別
- 北米市場規模・予測：流通チャネル別
- 北米市場規模・予測：国別
  - 米国
  - カナダ
  - メキシコ
欧州
- 主な動向と機会
- 欧州の市場規模・予測：適応症別
- 欧州市場規模・予測：薬物クラス別
- 欧州市場規模・予測：流通チャネル別
- 欧州市場規模・予測：国別
  - ドイツ
  - フランス
  - 英国
  - イタリア
  - スペイン
  - その他欧州
アジア太平洋地域
- 主な動向と機会
- アジア太平洋地域の市場規模・予測：適応症別
- アジア太平洋地域の市場規模・予測：薬物クラス別
- アジア太平洋地域の市場規模・予測：流通チャネル別
- アジア太平洋地域の市場規模・予測：国別
  - 中国
  - 日本
  - インド
  - 韓国
  - オーストラリア
  - その他アジア太平洋地域
LAMEA
- 主な動向と機会
- LAMEAの市場規模・予測：適応症別
- LAMEAの市場規模・予測：薬物クラス別
- LAMEAの市場規模・予測：流通チャネル別
- LAMEAの市場規模・予測：国別
  - ブラジル
  - サウジアラビア
  - 南アフリカ共和国
  - LAMEAの残りの地域

第8章企業情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合のヒートマップ
主な発展

第9章企業プロファイル

apotex inc.
Aurobindo Pharma Ltd
Biogen Idec
Eisai
Eli Lilly and Company
Johnson & Johnson
Abbvie Inc
F. Hoffmann-La Roche AG
Teva Pharmaceutical Industries
Novartis AG

図表

LIST OF TABLES

TABLE 1. GLOBAL DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 2. DEMENTIA DRUGS MARKET FOR LEWY BODY DEMENTIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. DEMENTIA DRUGS MARKET FOR LEWY BODY DEMENTIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. DEMENTIA DRUGS MARKET FOR PARKINSONS DISEASE DEMENTIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. DEMENTIA DRUGS MARKET FOR PARKINSONS DISEASE DEMENTIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 6. DEMENTIA DRUGS MARKET FOR ALZHEIMERS DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 7. DEMENTIA DRUGS MARKET FOR ALZHEIMERS DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 8. DEMENTIA DRUGS MARKET FOR VASCULAR DEMENTIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 9. DEMENTIA DRUGS MARKET FOR VASCULAR DEMENTIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 10. DEMENTIA DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. DEMENTIA DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 12. GLOBAL DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 13. DEMENTIA DRUGS MARKET FOR CHOLINESTERASE INHIBITORS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. DEMENTIA DRUGS MARKET FOR CHOLINESTERASE INHIBITORS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 15. DEMENTIA DRUGS MARKET FOR NMDA ANTAGONISTS AND ITS COMBINATION DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. DEMENTIA DRUGS MARKET FOR NMDA ANTAGONISTS AND ITS COMBINATION DRUGS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 17. GLOBAL DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 18. DEMENTIA DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 19. DEMENTIA DRUGS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 20. DEMENTIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 21. DEMENTIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 22. DEMENTIA DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 23. DEMENTIA DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 24. DEMENTIA DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 25. NORTH AMERICA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 26. NORTH AMERICA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 27. NORTH AMERICA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 28. NORTH AMERICA DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 29. U.S. DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 30. U.S. DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 31. U.S. DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 32. CANADA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 33. CANADA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 34. CANADA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 35. MEXICO DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 36. MEXICO DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 37. MEXICO DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 38. EUROPE DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 39. EUROPE DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 40. EUROPE DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 41. EUROPE DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 42. GERMANY DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 43. GERMANY DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 44. GERMANY DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 45. FRANCE DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 46. FRANCE DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 47. FRANCE DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 48. UK DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 49. UK DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 50. UK DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 51. ITALY DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 52. ITALY DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 53. ITALY DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 54. SPAIN DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 55. SPAIN DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 56. SPAIN DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 57. REST OF EUROPE DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 58. REST OF EUROPE DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 59. REST OF EUROPE DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 60. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 61. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 62. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 63. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 64. CHINA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 65. CHINA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 66. CHINA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 67. JAPAN DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 68. JAPAN DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 69. JAPAN DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 70. INDIA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 71. INDIA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 72. INDIA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 73. SOUTH KOREA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 74. SOUTH KOREA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 75. SOUTH KOREA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 76. AUSTRALIA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 77. AUSTRALIA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 78. AUSTRALIA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 79. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 80. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 81. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 82. LAMEA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 83. LAMEA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 84. LAMEA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 85. LAMEA DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 86. BRAZIL DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 87. BRAZIL DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 88. BRAZIL DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 89. SAUDI ARABIA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 90. SAUDI ARABIA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 91. SAUDI ARABIA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 92. SOUTH AFRICA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 93. SOUTH AFRICA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 94. SOUTH AFRICA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 95. REST OF LAMEA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 96. REST OF LAMEA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 97. REST OF LAMEA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 98.APOTEX INC.: COMPANY SNAPSHOT
TABLE 99.APOTEX INC.: OPERATING SEGMENTS
TABLE 100.APOTEX INC.: PRODUCT PORTFOLIO
TABLE 101.APOTEX INC.: NET SALES
TABLE 102.APOTEX INC.: KEY STRATERGIES
TABLE 103.AUROBINDO PHARMA LTD: COMPANY SNAPSHOT
TABLE 104.AUROBINDO PHARMA LTD: OPERATING SEGMENTS
TABLE 105.AUROBINDO PHARMA LTD: PRODUCT PORTFOLIO
TABLE 106.AUROBINDO PHARMA LTD: NET SALES
TABLE 107.AUROBINDO PHARMA LTD: KEY STRATERGIES
TABLE 108.BIOGEN IDEC: COMPANY SNAPSHOT
TABLE 109.BIOGEN IDEC: OPERATING SEGMENTS
TABLE 110.BIOGEN IDEC: PRODUCT PORTFOLIO
TABLE 111.BIOGEN IDEC: NET SALES
TABLE 112.BIOGEN IDEC: KEY STRATERGIES
TABLE 113.EISAI: COMPANY SNAPSHOT
TABLE 114.EISAI: OPERATING SEGMENTS
TABLE 115.EISAI: PRODUCT PORTFOLIO
TABLE 116.EISAI: NET SALES
TABLE 117.EISAI: KEY STRATERGIES
TABLE 118.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 119.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 120.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 121.ELI LILLY AND COMPANY: NET SALES
TABLE 122.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 123.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 124.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 125.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 126.JOHNSON & JOHNSON: NET SALES
TABLE 127.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 128.ABBVIE INC: COMPANY SNAPSHOT
TABLE 129.ABBVIE INC: OPERATING SEGMENTS
TABLE 130.ABBVIE INC: PRODUCT PORTFOLIO
TABLE 131.ABBVIE INC: NET SALES
TABLE 132.ABBVIE INC: KEY STRATERGIES
TABLE 133., F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 134., F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
TABLE 135., F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 136., F. HOFFMANN-LA ROCHE AG: NET SALES
TABLE 137., F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
TABLE 138.TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT
TABLE 139.TEVA PHARMACEUTICAL INDUSTRIES: OPERATING SEGMENTS
TABLE 140.TEVA PHARMACEUTICAL INDUSTRIES: PRODUCT PORTFOLIO
TABLE 141.TEVA PHARMACEUTICAL INDUSTRIES: NET SALES
TABLE 142.TEVA PHARMACEUTICAL INDUSTRIES: KEY STRATERGIES
TABLE 143.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 144.NOVARTIS AG: OPERATING SEGMENTS
TABLE 145.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 146.NOVARTIS AG: NET SALES
TABLE 147.NOVARTIS AG: KEY STRATERGIES

LIST OF FIGURES

FIGURE 1.DEMENTIA DRUGS MARKET SEGMENTATION
FIGURE 2.DEMENTIA DRUGS MARKET,2021-2031
FIGURE 3.DEMENTIA DRUGS MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.DEMENTIA DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.DEMENTIA DRUGS MARKET,BY INDICATION,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF LEWY BODY DEMENTIA DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF PARKINSONS DISEASE DEMENTIA DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ALZHEIMERS DISEASE DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF VASCULAR DEMENTIA DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHER INDICATIONS DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 18.DEMENTIA DRUGS MARKET,BY DRUG CLASS,2021(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CHOLINESTERASE INHIBITORS DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF NMDA ANTAGONISTS AND ITS COMBINATION DRUGS DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 21.DEMENTIA DRUGS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 25.DEMENTIA DRUGS MARKET BY REGION,2021
FIGURE 26.U.S. DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 27.CANADA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 28.MEXICO DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 29.GERMANY DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 30.FRANCE DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 31.UK DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 32.ITALY DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 33.SPAIN DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 34.REST OF EUROPE DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 35.CHINA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 36.JAPAN DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 37.INDIA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 38.SOUTH KOREA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 39.AUSTRALIA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 40.REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 41.BRAZIL DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 42.SAUDI ARABIA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 43.SOUTH AFRICA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 44.REST OF LAMEA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 48.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 49.COMPETITIVE DASHBOARD
FIGURE 50.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 51.APOTEX INC..: NET SALES ($MILLION)
FIGURE 52.AUROBINDO PHARMA LTD.: NET SALES ($MILLION)
FIGURE 53.BIOGEN IDEC.: NET SALES ($MILLION)
FIGURE 54.EISAI.: NET SALES ($MILLION)
FIGURE 55.ELI LILLY AND COMPANY.: NET SALES ($MILLION)
FIGURE 56.JOHNSON & JOHNSON.: NET SALES ($MILLION)
FIGURE 57.ABBVIE INC.: NET SALES ($MILLION)
FIGURE 58., F. HOFFMANN-LA ROCHE AG.: NET SALES ($MILLION)
FIGURE 59.TEVA PHARMACEUTICAL INDUSTRIES.: NET SALES ($MILLION)
FIGURE 60.NOVARTIS AG.: NET SALES ($MILLION)

Product Code: A12014

The global dementia drugs market accounted for $8662.17 million in 2021, and is expected to reach $19704.27 million by 2031, registering a CAGR of 8.5% from 2022 to 2031.

Dementia is a syndrome in which there is deterioration in thinking, behavior, memory, and ability to perform daily activities. The most common form of dementia is Alzheimer disease. Dementia results from many injuries and disease that primarily or secondarily impact the brain. There is often lack of awareness about dementia, which results in obstacles to examination and care. Cholinesterase Inhibitors are most commonly prescribed medicines, which help prevent break down of acetylcholine in the brain as acetylcholine is essential in learning, memory, and mood of individual.

It is estimated that the dementia drugs market is expected to experience significant market growth during the forecast period owing to increase in the prevalence of Alzheimer's disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis. In addition, the growing geriatric population, increase in investment by players in R&D and presence of robust pipeline candidates, rise in expenditure on the development of healthcare infrastructure, increase in public awareness about the disease prevention in developing regions, and surge in demand for personalized medicine, further facilitate the growth of the market. However, strict government regulation related to product approval and high cost linked to R&D activity are expected to impede the market growth. In contrast, accelerated technological advancement in drug discovery technique and high investment by the government for drug development are factors that present new pathway in the industry, which are anticipated to provide significant growth opportunities for the dementia drugs market.

The dementia drugs market is segmented on the basis of indication, drug class, distribution channel, and region. On the basis of indication, the market is bifurcated into Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease, vascular dementia, and other indications. Depending on drug class, the market is classified into cholinesterase inhibitors and NMDA antagonist and its combination drugs. By distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global dementia dugs market. The key companies profiled in the report include AbbVie Inc., APPOTEX Inc., Aurobindo Pharma Limited, Biogen Idec Inc., EISAI GLOBAL, Eli Lilly and company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG and Teva Pharmaceuticals

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the dementia drugs market analysis from 2021 to 2031 to identify the prevailing dementia drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the dementia drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global dementia drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Indication

Lewy Body Dementia
Parkinsons Disease Dementia
Alzheimers Disease
Vascular Dementia
Other Indications

By Drug Class

Cholinesterase Inhibitors
NMDA Antagonists and its Combination Drugs

By Distribution Channel

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- apotex inc.
- Aurobindo Pharma Ltd
- Biogen Idec
- Eisai
- Eli Lilly and Company
- Johnson & Johnson
- Abbvie Inc
- , F. Hoffmann-La Roche AG
- Teva Pharmaceutical Industries
- Novartis AG

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: DEMENTIA DRUGS MARKET, BY INDICATION

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Lewy Body Dementia
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market share analysis by country
4.3 Parkinsons Disease Dementia
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market share analysis by country
4.4 Alzheimers Disease
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market share analysis by country
4.5 Vascular Dementia
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market share analysis by country
4.6 Other Indications
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market share analysis by country

CHAPTER 5: DEMENTIA DRUGS MARKET, BY DRUG CLASS

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Cholinesterase Inhibitors
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market share analysis by country
5.3 NMDA Antagonists and its Combination Drugs
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market share analysis by country

CHAPTER 6: DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Retail Pharmacies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market share analysis by country
6.3 Hospital Pharmacies
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market share analysis by country
6.4 Online Pharmacies
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market share analysis by country

CHAPTER 7: DEMENTIA DRUGS MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Indication
- 7.2.3 North America Market size and forecast, by Drug Class
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Key market trends, growth factors and opportunities
  - 7.2.5.1.2 Market size and forecast, by Indication
  - 7.2.5.1.3 Market size and forecast, by Drug Class
  - 7.2.5.1.4 Market size and forecast, by Distribution Channel
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Key market trends, growth factors and opportunities
  - 7.2.5.2.2 Market size and forecast, by Indication
  - 7.2.5.2.3 Market size and forecast, by Drug Class
  - 7.2.5.2.4 Market size and forecast, by Distribution Channel
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Key market trends, growth factors and opportunities
  - 7.2.5.3.2 Market size and forecast, by Indication
  - 7.2.5.3.3 Market size and forecast, by Drug Class
  - 7.2.5.3.4 Market size and forecast, by Distribution Channel
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Indication
- 7.3.3 Europe Market size and forecast, by Drug Class
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Key market trends, growth factors and opportunities
  - 7.3.5.1.2 Market size and forecast, by Indication
  - 7.3.5.1.3 Market size and forecast, by Drug Class
  - 7.3.5.1.4 Market size and forecast, by Distribution Channel
  - 7.3.5.2 France
  - 7.3.5.2.1 Key market trends, growth factors and opportunities
  - 7.3.5.2.2 Market size and forecast, by Indication
  - 7.3.5.2.3 Market size and forecast, by Drug Class
  - 7.3.5.2.4 Market size and forecast, by Distribution Channel
  - 7.3.5.3 UK
  - 7.3.5.3.1 Key market trends, growth factors and opportunities
  - 7.3.5.3.2 Market size and forecast, by Indication
  - 7.3.5.3.3 Market size and forecast, by Drug Class
  - 7.3.5.3.4 Market size and forecast, by Distribution Channel
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Key market trends, growth factors and opportunities
  - 7.3.5.4.2 Market size and forecast, by Indication
  - 7.3.5.4.3 Market size and forecast, by Drug Class
  - 7.3.5.4.4 Market size and forecast, by Distribution Channel
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Key market trends, growth factors and opportunities
  - 7.3.5.5.2 Market size and forecast, by Indication
  - 7.3.5.5.3 Market size and forecast, by Drug Class
  - 7.3.5.5.4 Market size and forecast, by Distribution Channel
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Key market trends, growth factors and opportunities
  - 7.3.5.6.2 Market size and forecast, by Indication
  - 7.3.5.6.3 Market size and forecast, by Drug Class
  - 7.3.5.6.4 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Indication
- 7.4.3 Asia-Pacific Market size and forecast, by Drug Class
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 China
  - 7.4.5.1.1 Key market trends, growth factors and opportunities
  - 7.4.5.1.2 Market size and forecast, by Indication
  - 7.4.5.1.3 Market size and forecast, by Drug Class
  - 7.4.5.1.4 Market size and forecast, by Distribution Channel
  - 7.4.5.2 Japan
  - 7.4.5.2.1 Key market trends, growth factors and opportunities
  - 7.4.5.2.2 Market size and forecast, by Indication
  - 7.4.5.2.3 Market size and forecast, by Drug Class
  - 7.4.5.2.4 Market size and forecast, by Distribution Channel
  - 7.4.5.3 India
  - 7.4.5.3.1 Key market trends, growth factors and opportunities
  - 7.4.5.3.2 Market size and forecast, by Indication
  - 7.4.5.3.3 Market size and forecast, by Drug Class
  - 7.4.5.3.4 Market size and forecast, by Distribution Channel
  - 7.4.5.4 South Korea
  - 7.4.5.4.1 Key market trends, growth factors and opportunities
  - 7.4.5.4.2 Market size and forecast, by Indication
  - 7.4.5.4.3 Market size and forecast, by Drug Class
  - 7.4.5.4.4 Market size and forecast, by Distribution Channel
  - 7.4.5.5 Australia
  - 7.4.5.5.1 Key market trends, growth factors and opportunities
  - 7.4.5.5.2 Market size and forecast, by Indication
  - 7.4.5.5.3 Market size and forecast, by Drug Class
  - 7.4.5.5.4 Market size and forecast, by Distribution Channel
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Key market trends, growth factors and opportunities
  - 7.4.5.6.2 Market size and forecast, by Indication
  - 7.4.5.6.3 Market size and forecast, by Drug Class
  - 7.4.5.6.4 Market size and forecast, by Distribution Channel
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Indication
- 7.5.3 LAMEA Market size and forecast, by Drug Class
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Key market trends, growth factors and opportunities
  - 7.5.5.1.2 Market size and forecast, by Indication
  - 7.5.5.1.3 Market size and forecast, by Drug Class
  - 7.5.5.1.4 Market size and forecast, by Distribution Channel
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Key market trends, growth factors and opportunities
  - 7.5.5.2.2 Market size and forecast, by Indication
  - 7.5.5.2.3 Market size and forecast, by Drug Class
  - 7.5.5.2.4 Market size and forecast, by Distribution Channel
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Key market trends, growth factors and opportunities
  - 7.5.5.3.2 Market size and forecast, by Indication
  - 7.5.5.3.3 Market size and forecast, by Drug Class
  - 7.5.5.3.4 Market size and forecast, by Distribution Channel
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Key market trends, growth factors and opportunities
  - 7.5.5.4.2 Market size and forecast, by Indication
  - 7.5.5.4.3 Market size and forecast, by Drug Class
  - 7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 apotex inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Aurobindo Pharma Ltd
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Biogen Idec
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Eisai
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Eli Lilly and Company
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 Johnson & Johnson
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Abbvie Inc
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 , F. Hoffmann-La Roche AG
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Teva Pharmaceutical Industries
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 Novartis AG
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments

認知症治療薬市場：適応症別、薬物クラス別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Dementia Drugs Market By Indication, By Drug Class, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章認知症治療薬市場：適応症別

第5章認知症治療薬市場：薬効分類別

第6章認知症治療薬市場：流通チャネル別

第7章認知症治療薬市場：地域別

第8章企業情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: DEMENTIA DRUGS MARKET, BY INDICATION

CHAPTER 5: DEMENTIA DRUGS MARKET, BY DRUG CLASS

CHAPTER 6: DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: DEMENTIA DRUGS MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

認知症治療薬市場：適応症別、薬物クラス別、流通チャネル別：世界の機会分析および産業予測、2021-2031年

Dementia Drugs Market By Indication, By Drug Class, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

第4章 認知症治療薬市場：適応症別

第5章 認知症治療薬市場：薬効分類別

第6章 認知症治療薬市場：流通チャネル別

第7章 認知症治療薬市場：地域別

第8章 企業情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Market Segments

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

CHAPTER 2:EXECUTIVE SUMMARY

CHAPTER 3:MARKET OVERVIEW

CHAPTER 4: DEMENTIA DRUGS MARKET, BY INDICATION

CHAPTER 5: DEMENTIA DRUGS MARKET, BY DRUG CLASS

CHAPTER 6: DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 7: DEMENTIA DRUGS MARKET, BY REGION

CHAPTER 8: COMPANY LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場の概要

第4章認知症治療薬市場：適応症別

第5章認知症治療薬市場：薬効分類別

第6章認知症治療薬市場：流通チャネル別

第7章認知症治療薬市場：地域別

第8章企業情勢

第9章企業プロファイル